Suven Life Sciences Ltd. — Investor Relations & Filings
Suven Life Sciences Ltd. focuses on the discovery and development of novel therapeutic agents for Central Nervous System (CNS) disorders. The company specializes in New Chemical Entity (NCE) research, targeting unmet medical needs in conditions such as Alzheimer’s disease, schizophrenia, attention deficit hyperactivity disorder (ADHD), Huntington’s disease, Parkinson’s disease, and depression. Its clinical pipeline includes lead candidates like Masupirdine (SUVN-502) for cognitive impairment and Samelisant (SUVN-G3031) for narcolepsy. Suven utilizes an integrated drug discovery platform and maintains a significant global intellectual property portfolio. The organization provides drug discovery and development support services, leveraging expertise in medicinal chemistry and pharmacology to advance internal programs and collaborative research initiatives.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Copy of Newspaper Publication | 2026-04-23 | English | |
| Price movement | 2026-04-08 | English | |
| Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 2026-04-06 | English | |
| Trading Window | 2026-03-27 | English | |
| Outcome of Board Meeting | 2026-03-06 | English | |
| Allotment of Securities | 2026-03-06 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 42171737 | Copy of Newspaper Publication | 2026-04-23 | English | ||
| 42187106 | Price movement | 2026-04-08 | English | ||
| 42208254 | Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 2026-04-06 | English | ||
| 42223422 | Trading Window | 2026-03-27 | English | ||
| 42197228 | Outcome of Board Meeting | 2026-03-06 | English | ||
| 42197303 | Allotment of Securities | 2026-03-06 | English | ||
| 42168398 | Copy of Newspaper Publication | 2026-02-19 | English | ||
| 42295958 | Price movement | 2026-02-06 | English | ||
| 42221508 | Monitoring Agency Report | 2026-02-03 | English | ||
| 42258219 | Copy of Newspaper Publication | 2026-01-30 | English | ||
| 42179002 | Appointment | 2026-01-29 | English | ||
| 42179326 | Resignation | 2026-01-29 | English | ||
| 42179815 | Outcome of Board Meeting | 2026-01-29 | English | ||
| 42180211 | Outcome of Board Meeting | 2026-01-29 | English | ||
| 43866134 | Board Meeting — Board Meeting Intimation | 2026-01-22 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Compugen Ltd.
A clinical-stage company developing cancer immunotherapies …
|
CGEN | IL | Professional, scientific and te… |
|
COMPUGEN LTD
A clinical-stage company using AI to discover cancer immuno…
|
CGEN | US | Professional, scientific and te… |
|
Core One Labs Inc.
Biotechnology research and technology developing and commer…
|
COOL | CA | Professional, scientific and te… |
|
CORESTEMCHEMON Inc.
Develops stem cell therapies and provides non-clinical CRO …
|
166480 | KR | Professional, scientific and te… |
|
CRONEX.CO.,LTD
A CRO supplying biological species and bio-tissue materials…
|
215570 | KR | Professional, scientific and te… |
|
C&R Research Inc.
A full-service CRO providing clinical research for pharma a…
|
359090 | KR | Professional, scientific and te… |
|
CSG Digital Power Grid Research Institute Co.,Ltd.
Develops AI, IoT, and digital grid technologies for power s…
|
301638 | CN | Professional, scientific and te… |
|
CTC - CENTRO DE TECNOLOGIA CANAVIEIRA S.A.
Develops advanced sugarcane varieties to optimize agricultu…
|
— | BR | Professional, scientific and te… |
|
Cte Group Spolka Akcyjna
Diversified firm in HR services, corporate events, and comp…
|
LPS | PL | Professional, scientific and te… |
|
curacle co., ltd.
A clinical-stage biopharma developing drugs for intractable…
|
365270 | KR | Professional, scientific and te… |
Suven Life Sciences Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/61491/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=61491 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=61491 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=61491 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 61491}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Suven Life Sciences Ltd. (id: 61491)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.